DOCSLIB.ORG

Evidence of an Early Information Processing Speed Deficit in Unipolar

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence of an Early Information Processing Speed Deficit in Unipolar Psychological Medicine, 2002, 32, 259–265. " 2002 Cambridge University Press DOI: 10.1017\S0033291701005001 Printed in the United Kingdom Evidence of an early information processing speed deficit in unipolar major depression " G.TSOURTOS, J.C.THOMPSON C.STOUGH From the Department of Psychiatry, University of Adelaide, South Australia; and Neuropsychology Laboratory and Brain Sciences Institute, Swinburne University, Victoria, Australia ABSTRACT Background. Slowing of the speed of information processing has been reported in geriatric depression, but it is not clear if the impairment is present in younger patients, if motor retardation is responsible, or if antidepressant medications play a role. Method. Twenty unmedicated unipolar depressed inpatients were compared with 19 medicated depressed in-patients and 20 age-, sex- and verbal IQ-matched controls on inspection time (IT), a measure of speed of information processing that does not require a speeded motor response. We also examined the relationship between IT and current mood and length of depressive illness. Results. Unmedicated depressed patients showed slowing of information processing speed when compared to both medicated depressed patients and controls. The latter two groups were not significantly different from each other. Slowing of IT was not associated with current mood, but was negatively correlated with length of illness since first episode. No differences in IT were found between patients receiving medication with anticholinergic effects and patients receiving medication with no anticholinergic effects. Conclusions. The findings indicate that unipolar depression is associated with a slowing of speed of information processing in younger patients who have not received antidepressant medication. This does not appear to be a result of motor slowing. memory impairments, medicated neuropsycho- INTRODUCTION logical impairment in patients with geriatric Patients suffering depression often report the depression. Both motor and cognitive speed subjective experience of a slowing in mental appear to be impaired in depression (Sobin & speed (O’Connor et al. 1990). Cognitive slowing Sackheim, 1997; Calgiuri & Ellwanger, 2000), may contribute to neuropsychological impair- although Elliott et al. (1996) found that middle- ment associated with unipolar major depression aged (mean age 49 years) depressed patients (MD), as well as depression secondary to other were impaired on a measure of cognitive speed illnesses (Brebion et al. 2000; Fann et al. 2001). but not motor speed. For example, Brown et al. (1994) reported that In contrast to these findings, Purcell et al. elderly (& 65 years old) depressed patients (1997) reported that younger patients (mean age showed slower performance on a range of 37 years) were impaired on measures of atten- neuropsychological tests than age-matched con- tional set-shifting and planning, but not cog- trols. Nebes et al. (2000) reported that slowing nitive speed. It was concluded by Purcell et al. of information speed, as well as working (1997) that younger patients with depression do not show the cognitive slowing that is reported " in middle-aged and older patients. A problem Address for correspondence: Professor Con Stough, Neuro- psychology Laboratory, Swinburne University, PO Box 218 Haw- with this interpretation is that the cognitive thorn, Victoria 3122, Australia. speed measure used by both Elliott et al. (1996) 259 260 G. Tsourtos and others and Purcell et al. (1997) was time to respond 1987). Subjects are instructed to take as long as (‘thinking time’) during a planning task (the necessary to respond, and to focus on accuracy. Cambridge Neuropsychological Test Auto- A preliminary study by Tsourtos et al. (1995) mated Battery (CANTAB) Tower of London). reported that a mixed group of psychiatric in- As this measure involves a number of cognitive patients diagnosed with either depression, schizo- operations including processing speed, it is phrenia, mania or anxiety disorder had signifi- unclear if one can conclude from Purcell et al.’s cantly longer ITs than a healthy control group. (1997) study that younger depressed patients do The present study examined IT performance not show cognitive slowing. Tarbuck & Paykel in unipolar depressed in-patients of a similar age (1995) reported that older depressed patients to those in the study by Purcell et al. (1997). It (mean age 69 years) were slower than younger was hypothesized that the depressed patients depressed patients (mean age 41 years) on a would be impaired relative to age-, sex- and IQ- choice reaction time (RT) measure. However, matched control subjects. Many studies of the RT improved to a similar extent in both groups neuropsychological profile of depression have following recovery, indicating that both age and included medicated and unmedicated patients depression may affect information processing within the same group (Austin et al. 1992; speed, but these variables do not interact to Tarbuck & Paykel, 1996; Purcell et al. 1997). In produce cognitive slowing in older depressed order to examine if medication has an effect on but not younger depressed. The aim of the IT in depression, medicated and unmedicated present study was therefore to examine if speed subjects were grouped separately in the present of information processing was slowed in young, study. As our previous research has indicated unipolar depressed individuals. that anticholinergic drugs can impair IT Most measures of information processing (Thompson et al. 2000; Waterham et al. 2002), speed rely on reaction item (RT) as the de- we compared patients receiving antidepressants pendent variable. Measures of RT can often be with anticholinergic effects to those receiving confounded by changes to motor speed. While antidepressants with minimal anticholinergic many methodologies allow for the separation of actions. Depressive symptoms and history have movement time (MT) and decision time (DT) also been reported by some studies to be related from RT, DT still measures the speed of both to cognitive impairment in some studies (Austin the perception and encoding of a stimulus, and et al. 1992) but not others (Purcell et al. 1997; the initiation of a motor action. The DT\MT Schatzberg et al. 2000), thus the relationship paradigm is also constrained by subjects being between level of depression, depressive history able to adopt varying speed-accuracy trade-off and IT were examined. strategies, as accuracy can be increased at the expense of response time. Unlike RT procedures METHOD the inspection time (IT) procedure is widely regarded as a measure of the speed of early Subjects stages of information processing that is not Twenty unmedicated and 19 medicated sensitive to motor speed, speed-accuracy trade- depressed in-patients from a psychiatric ward in offs or other cognitive strategies (Nettelbeck, a general hospital in Adelaide, South Australia 1987; Deary & Stough, 1996). Avoiding tasks in who were clinically diagnosed with (MD) accord- which strategies can improve performance is ing to the DSM-III-R criteria, together with 20 crucial in assessing cognition in depression, as healthy controls, match for age, sex and IQ par- depressed individuals are often impaired in the ticipated. Patients diagnosed with any history of deployment of effective cognitive strategies substance abuse, neurological injury, or con- (Channon & Green, 1999). IT is a measure current psychiatric disorder were excluded. An defined as the minimum duration of stimulus initial informal interview with the control presentation required for near perfect response subjects was used to establish any evidence of on a two-choice visual discrimination task. The substance abuse, neurological injury, or family stimulus duration is controlled by superimposing history of psychiatric illness. The vocabulary a backward mask over the stimulus which subscale from the Weschler Adult Intelligence prevents extended iconic sampling (Nettelbeck, Scale – Revised (WAIS-R; Weschler, 1987) was Information processing in depression 261 item scale (standardized scores range between Table 1. Means (..) of the demographic 25–100) of depression experienced in the past, variables and a visual analogue scale (VAS, scores range Age Sex Vocabulary between 0–10) measuring the extent of depres- sion currently experienced. Additional infor- Unmedicated (N l 20) 39n4 (13n6) 12 F 39n6 (13n3) mation was gathered about the patient’s length Medicated (N l 19) 36n1 (12n8) 15 F 39n5 (13n0) Controls (N l 20) 35n8 (13n7) 14 F 40n3 (11n4) of illness both current episode (weeks) and from initial onset (number of weeks since first episode). The type, dosage (mg\day) and length Table 2. Medication of depressed patients in the of medication administered to the medicated non-cholinergic and anticholinergic medication group was also retrospectively recorded from groups hospital drug charts after drug administration. Subject No. Medication Dose\day mg Inspection time Non-cholinergic An IBM compatible PC with a 14 inch monitor 1 Fluoxetine 20 was used to display the monochrome visual IT 2 Moclobemide 150 task with an accompanying 12 12 cm two 3 Fluoxetine 20 i 4 Moclobemide 500 response choice panel. The two buttons were 5 Moclobemide 150 17 mm in diameter and spaced 107 mm apart. 6 Fluoxetine 20 7 Tranylcypromine 70 To measure IT, a small central circular cue 8 Sertraline 50 appeared prior to the stimulus for 500 ms. The 9 Fluoxetine 20 stimulus was composed of two vertical lines, one 10 Lithium 500 29 mm in length, the other,
Load more

Recommended publications
  • Maturation and Development. Biological and Psychological Perspectives
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.375-b on 1 April 1983. Downloaded from Journal of Neurology, Neurosurgery, and Psychiatry 1983;46:375-376 definition by trained transcribers with an tumours in childhood. Book reviews interexaminer reliability of F = 0-81 fol- These volumes are much recommended Gilies de la Tourette Syndrome Volume 35 lowed by 2-way Anovas with blocking for to all neurosurgeons who wish to be of Advances in Neurology. Edited by subject pairs to compute F ratios for com- acquainted with the "state of play" in Arnold J Friedhoff and Thomas N Chase. paring the mean Z scores on each language paediatric neurosurgery. The editors are, (Pp 478; $58.90.) New York, Raven Press. function. This is incomprehensible as well however, very naive if they believe, as they 1982. as meaningless. It is impossible to find out suggest in their preface to volume 2, that it whether clonidine is really useful or not or may be "possible for paediatric This volume contains the proceedings of whether haloperidol does possess definite neurosurgeons throughout the entire world the 1981 New York symposium on advantages over other neuroleptics. to provide their knowledge and care to the Tourette syndrome. The 67 papers are This is the second major work on Gilles benefit of all children". At least 1000 mil- organised into 10 main sections, clinical de la Tourette's syndrome to appear in 4 lion of the world's population are provided and historical over-view, neuro-anatomy years, the first edited by the Shapiros, with very few neurosurgeons (for the and neuropathology, neurophysiology, Bruun, and Sweet.
    [Show full text]
  • Strategies for Managing Sexual Dysfunction Induced by Antidepressant Medication
    King’s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published version (APA): Taylor, M. J., Rudkin, L., Bullemor-Day, P., Lubin, J., Chukwujekwu, C., & Hawton, K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, (5). https://doi.org/10.1002/14651858.CD003382.pub3 Citing this paper Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections. General rights Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights. •Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research. •You may not further distribute the material or use it for any profit-making activity or commercial gain •You may freely distribute the URL identifying the publication in the Research Portal Take down policy If you believe that this document breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • European Journal of Pharmacology 753 (2015) 2–18
    European Journal of Pharmacology 753 (2015) 2–18 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.elsevier.com/locate/ejphar Review Serotonin: A never-ending story Berend Olivier a,b,n a Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences & Brain Center Rudolf Magnus, Utrecht University, Universiteitsweg 99, 3584CG Utrecht, The Netherlands b Department of Psychiatry, Yale University School of Medicine, New Haven, USA article info abstract Article history: The neurotransmitter serotonin is an evolutionary ancient molecule that has remarkable modulatory Accepted 16 October 2014 effects in almost all central nervous system integrative functions, such as mood, anxiety, stress, aggression, Available online 7 November 2014 feeding, cognition and sexual behavior. After giving a short outline of the serotonergic system (anatomy, Keywords: receptors, transporter) the author's contributions over the last 40 years in the role of serotonin in Serotonin depression, aggression, anxiety, stress and sexual behavior is outlined. Each area delineates the work Depression performed on animal model development, drug discovery and development. Most of the research work Anxiety described has started from an industrial perspective, aimed at developing animals models for psychiatric Aggression diseases and leading to putative new innovative psychotropic drugs, like in the cases of the SSRI SSRI fluvoxamine, the serenic eltoprazine and the anxiolytic flesinoxan. Later this research work mainly focused Fluvoxamine on developing translational animal models for psychiatric diseases and implicating them in the search for mechanisms involved in normal and diseased brains and finding new concepts for appropriate drugs. & 2014 Elsevier B.V. All rights reserved. Contents 1. Serotonin, history, drugs .
    [Show full text]
  • Tcas Versus Placebo - New Studies in the Guideline Update
    TCAs versus placebo - new studies in the guideline update Comparisons Included in this Clinical Question Amitriptyline vs placebo Clomipramine vs placebo Dosulepin (dothiepin) vs placebo AMSTERDAM2003A LARSEN1989 FERGUSON1994B BAKISH1992B PECKNOLD1976B ITIL1993 BAKISH1992C RAMPELLO1991 MINDHAM1991 BREMNER1995 THOMPSON2001B CLAGHORN1983 CLAGHORN1983B FEIGHNER1979 GELENBERG1990 GEORGOTAS1982A GOLDBERG1980 HICKS1988 HOLLYMAN1988 HORMAZABAL1985 HOSCHL1989 KLIESER1988 LAAKMAN1995 LAPIERRE1991 LYDIARD1997 MYNORSWALLIS1995 MYNORSWALLIS1997 REIMHERR1990 RICKELS1982D RICKELS1985 RICKELS1991 ROFFMAN1982 ROWAN1982 SMITH1990 SPRING1992 STASSEN1993 WILCOX1994 16 Imipramine vs placebo BARGESCHAAPVELD2002 BEASLEY1991B BOYER1996A BYERLEY1988 CASSANO1986 CASSANO1996 CLAGHORN1996A COHN1984 COHN1985 COHN1990A COHN1992 COHN1996 DOMINGUEZ1981 DOMINGUEZ1985 DUNBAR1991 ELKIN1989 ENTSUAH1994 ESCOBAR1980 FABRE1980 FABRE1992 FABRE1996 FEIGER1996A FEIGHNER1980 FEIGHNER1982 FEIGHNER1983A FEIGHNER1983B FEIGHNER1989 FEIGHNER1989A FEIGHNER1989B FEIGHNER1989C FEIGHNER1992B FEIGHNER1993 FONTAINE1994 GELENBERG2002 GERNER1980B HAYES1983 ITIL1983A KASPER1995B KELLAMS1979 LAIRD1993 LAPIERRE1987 LECRUBIER1997B LIPMAN1986 LYDIARD1989 MARCH1990 17 MARKOWITZ1985 MENDELS1986 MERIDETH1983 Nortriptyline vs placebo NANDI1976 GEORGOTAS1986A NORTON1984 KATZ1990 PEDERSEN2002 NAIR1995 PESELOW1989 WHITE1984A PESELOW1989B PHILIPP1999 QUITKIN1989 RICKELS1981 RICKELS1982A RICKELS1987 SCHWEIZER1994 SCHWEIZER1998 SHRIVASTAVA1992 SILVERSTONE1994 SMALL1981 UCHA1990 VERSIANI1989 VERSIANI1990
    [Show full text]
  • Antidepressant Prophylaxis Reduces Depression Risk but Does Not
    REVIEW Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C patients receiving interferon without depression at baseline: A systematic review and meta-analysis Awad Al-Omari MD1, Juthaporn Cowan MD1, Lucy Turner BSc MSc2, Curtis Cooper MD FRCPC1,2 A Al-Omari, J Cowan, L Turner, C Cooper. Antidepressant Les antidépresseurs en prophylaxie réduisent le risque de prophylaxis reduces depression risk but does not improve dépression mais n’améliorent pas la réponse virologique sustained virological response in hepatitis C patients receiving soutenue chez les patients atteints d’hépatite C qui interferon without depression at baseline: A systematic review reçoivent de l’interféron sans être déprimés au départ : and meta-analysis. Can J Gastroenterol 2013;27(10):575-581. une analyse systématique et une méta-analyse BACKGROUND: Depression complicates interferon-based hepatitis C HISTORIQUE : La dépression complique l’antivirothérapie à l’interféron virus (HCV) antiviral therapy in 10% to 40% of cases, and diminishes conte le virus de l’hépatite C (VHC) chez 10 % à 40 % des patients et patient well-being and ability to complete a full course of therapy. As réduit leur bien-être et leur capacité de terminer le traitement. Par con- a consequence, the likelihood of achieving a sustained virological séquent, la probabilité d’obtenir une réponse virologique soutenue (RVS response (SVR [ie, permanent viral eradication]) is reduced. [c.-à-d. une éradication virale permanente]) est réduite. OBJECTIVE: To systematically review the evidence of whether pre- OBJECTIF : Procéder à l’analyse systématique des données probantes emptive antidepressant prophylaxis started before HCV antiviral pour déterminer si une prophylaxie préventive aux antidépresseurs amor- initiation is beneficial.
    [Show full text]
  • Typical and Atypical Antidepressants. Clinical Practice
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.46.4.376-a on 1 April 1983. Downloaded from 376 Book reviews concepts of "maturational delay" are most advance in terms of selectivity and fre- decessors. The anatomy is comprehensive often invoked. Ronnie would have been quency of unwanted effects. What has also and provides satisfying detail for both the especially disappointed by the last of these interested psychopharmacologists is the neuroanatomy student and the clinician. omissions but perhaps it was not discussed great variation in pharmacological effects Although it remains a predominantly because the queries he raised have yet to be between the new antidepressants. As yet anatomical text, it includes adequate answered and because there is little new to there is no satisfactory correlation between descriptions of related physiology, and report. The book deserves to be widely read their clinical effects and pharmacological where relevant, clinical topics are as much for the implicit unanswered actions but if it can be demonstrated that explained in brief vignettes. Some of these questions that arise, as for the wealth of they are effective antidepressants it shows are masterpieces of succinct, accurate and factual information it provides. that the old catecholamine hypothesis of illuminating writing. MICHAEL RUTTER affective disorders is untenable. In this vol- The clinical applications of anatomy and ume there is undeniable evidence that sev- physiology are explained for example in eral of the newer drugs are highly effective tests of vestibular function, visual fixation Low Back Pain-Assessment and Man- antidepressants, including bupropion, and muscle stretch reflexes. The correla- agement.
    [Show full text]
  • Dawson, S., Maund, E., Stuart, B., Moore, M., Christopher, D
    Dawson, S. , Maund, E., Stuart, B., Moore, M., Christopher, D., Geraghty, A. WA., & Kendrick, T. (2019). Managing Antidepressant Discontinuation: A Systematic Review. Annals of Family Medicine, 17(1), 52-60. https://doi.org/10.1370/afm.2336 Peer reviewed version License (if available): Other Link to published version (if available): 10.1370/afm.2336 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via the Annals of Family Medicine at https://doi.org/10.1370/afm.2336 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Supplemental materials for: Maund E, Stuart B, Moore M, et al. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52-60. 1 Supplemental APPENDIX 1 - SEARCH STRATEGIES MEDLINE Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to 23 March 2017 Search Query Items ID# found 1 exp ANTIDEPRESSIVE AGENTS/ 133782 2 exp NEUROTRANSMITTER UPTAKE INHIBITORS/ 133192 3 (psychotropic* or antidepress* or anti depress* or ((serotonin or norepinephrine or 136112 noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) and (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or tricyclic* or tetracyclic* or heterocyclic*).ti,kf,hw.
    [Show full text]
  • PRODUCT MONOGRAPH NOVO–FLUVOXAMINE (Fluvoxamine Maleate) Tablets Antidepressant/Antiobsessional Agent Teva Canada Limited
    PRODUCT MONOGRAPH NOVO–FLUVOXAMINE (Fluvoxamine Maleate) Tablets Antidepressant/Antiobsessional Agent Teva Canada Limited Date of Preparation: Toronto, Canada June 6, 2014 Control # 174215 PRODUCT MONOGRAPH NOVO-FLUVOXAMINE (Fluvoxamine Maleate) Tablets THERAPEUTIC CLASSIFICATION Antidepressant/Antiobsessional Agent ACTION AND CLINICAL PHARMACOLOGY The antidepressant and antiobsessional actions of fluvoxamine are believed to be related to its selective inhibition of presynaptic serotonin re-uptake in brain neurons. There is minimum interference with noradrenergic processes and, in common with several other specific inhibitors of serotonin uptake, fluvoxamine has very little in vitro affinity for α1, α2, β1, dopamine2, histamine1, serotonin1,serotonin2 or muscarinic receptors. Pharmacokinetics In healthy volunteers, fluvoxamine is well absorbed after oral administration. Following a single 100 mg oral dose, peak plasma levels of 31-87 ng/mL were attained 1.5 to 8 hours post-dose. Peak plasma levels and AUC's (0-72 hours) are directly proportionate to dose after single oral doses of 25, 50, and 100 mg. Following single doses, the mean plasma half-life is 15 hours, and slightly longer (17-22 hours), during repeated dosing. Steady-state plasma levels are usually achieved within 10-14 days. The pharmacokinetic profile in the elderly is similar to that in younger patients. Metabolism and Elimination Fluvoxamine undergoes extensive hepatic transformation, mainly via oxidative demethylation, to at least nine metabolites, which are excreted by the kidney. Ninety-four percent of an oral radioactive dose is recovered in the urine within 48 hours. The two major metabolites showed negligible pharmacological activity. In vitro binding of fluvoxamine to human plasma proteins is about 77% at drug concentrations up to 4000 ng/mL.
    [Show full text]
  • Drugs/Medications Known to Cause Hyperhidrosis Certain Prescriptions
    Drugs/Medications Known to Cause Hyperhidrosis Certain prescriptions and non-prescription medications can cause hyperhidrosis (excess perspiration or sweating) as a side effect. A list of potentially sweat-inducing medications is provided below. Medications are listed alphabetically by generic name. U.S. brand names are given in parentheses, if applicable. This list is provided as a resource and a service. It is not exhaustive and is in no way meant to replace consultation with a medical professional. Although sweating is a known side effect of the medications listed below, in most cases only a small percentage of people using the medicines experience undue sweating (in some cases less than 1%). Medications noted with an “*” and in bold are the most likely to cause sweating and the frequency of sweating as a side effect from these medications may be as high as 50%. Medications noted with an “†” are commonly-prescribed drugs; and those with a “P” are often used for pediatrics. Key: */Bold -- Known to commonly cause hyperhidrosis † -- Commonly-prescribed drugs P -- Pediatric use Abciximab (ReoPro®) Acamprosate (Campral®) Acetaminophen and Tramadol (Ultracet™) Acetophenazine (NA) Acetylcholine (Miochol-E®) P Acetylcysteine (Acetadote®) P Acitretin (Soriatane®) Acrivastine and Pseudoephedrine (Semprex®-D) † Acyclovir (Zovirax®) P Adenosine (Adenocard®; Adenoscan®) † Albuterol (Proventil® HFA Inhalation Aerosol) Alemtuzumab (Campath®) Alizapride (NA) Almotriptan (Axert™) Alosetron (Lotronex®) Amonafide (NA) Ambenonium (Mytelase®) Amitriptyline
    [Show full text]
  • Antidepressant Treatment for Postnatal Depression
    This is a repository copy of Antidepressant treatment for postnatal depression. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/163986/ Version: Published Version Article: Brown, Jennifer Valeska Elli orcid.org/0000-0003-0943-5177, Wilson, Claire A., Ayre, Karyn et al. (5 more authors) (2020) Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews. CD013560. ISSN 1469-493X https://doi.org/10.1002/14651858.CD013560 Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Cochrane Library Cochrane Database of Systematic Reviews Antidepressant treatment for postnatal depression (Protocol) Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H Brown JVE, Wilson CA, Ayre K, South E, Molyneaux E, Trevillion K, Howard LM, Khalifeh H. Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews 2020, Issue 3. Art. No.: CD013560. DOI: 10.1002/14651858.CD013560. www.cochranelibrary.com Antidepressant treatment for postnatal depression (Protocol) Copyright © 2020 The Cochrane Collaboration.
    [Show full text]
  • Letters to the Editor
    Letters to the Editor Letters to the Editor ©Mirtazapine-Associated Copyright 2001 Palinopsia Physicianswithdrawal Postgraduate of mirtazapine suggests Press, that mirtazapineInc. might have been the trigger for the phenomenon. Trazodone, nefazo- Sir: Mirtazapine is a combined noradrenergic and selective done, risperidone, and mirtazapine share antagonism at the serotonergic antagonist that is effective in the treatment of de- 5-HT2 receptor. LSD is a 5-HT2A and 5-HT2C agonist, and post- pression. The most common side effects of mirtazapine include hallucinogen perception disorder might be related to reduced dry mouth, drowsiness, sedation, increased appetite, and weight receptor stimulation. Our patient’s visual disturbance lends sup- gain.1 We report an unusual visual disturbance in one of our pa- port to the hypothesis that palinopsia is associated with 5-HT2 tients. antagonism or reduced 5-HT2 receptor stimulation. REFERENCES Case report. Ms. A, a 26-year-old woman with obsessive- compulsive personality disorder, sought treatment for her first 1. Montgomery SA. Safety of mirtazapine: a review. Int Clin major depressive episode, which was moderate and without psy- Psychopharmacol 1995;10(suppl 4):37–45 chotic features (DSM-IV). She had developed significant de- 2. Pomeranz HD, Lessell S. Palinopsia and polyopia in the absence pressed and irritable mood, restlessness,One increased personal anxiety, copy may beof drugs printed or cerebral disease. Neurology 2000;54:855–859 decreased appetite, and initial insomnia. She had a positive fam- 3. Kawasaki A, Purvin VA. Persistent palinopsia following ingestion of ily history for depression and felt that the depressive symptoms lysergic acid diethylamide (LSD). Arch Ophtalmol 1996;114:47–50 had an association with a significant life transition.
    [Show full text]